Journal of Autism and Developmental Disorders

, Volume 31, Issue 1, pp 109–113 | Cite as

Brief Report: Effects of Clozapine on Self-Injurious Behavior of Two Risperidone Nonresponders with Mental Retardation

  • Ron Hammock
  • William R. Levine
  • Stephen R. Schroeder


A typical antipsychotic medications for self-injurious behavior (SIB), aggression, and destruction among people with mental retardation and development disabilities are becoming increasingly accepted. Most studies are on risperidone and fewer have been conducted on clozapine. The present single-blind study reports marked reductions in SIB and aggression of two persons with profound mental retardation who were nonresponsive to all other behavioral and psychopharmacological interventions, including risperidone. The most effective dose was 200 mg/day. Side effects were mild and the drug was tolerated well.

Self-injurious behavior risperidone clozapine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aman, M. G., & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5251-260.Google Scholar
  2. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal on Mental Deficiency, 89492-502.Google Scholar
  3. Breese, G. R., Criswell, H. E., Duncan, G. E., Moy, S. S., Johnson, K. B., Wong, D. F., & Mueller, R. E. (1995). Model for reduced dopamine in Lesch-Nyhan syndrome and the mentally retarded: Neurobiology of neonatal-6-hydroxydopamine-lesioned rats. Mental Retardation and Developmental Disabilities Research Reviews, 1111-119.Google Scholar
  4. Buzan, R. A., Dubovsky, S. H., Firestone, D., & Dal Pozzo, E. (1998). Use of clozapine in 10 mentally retarded patients. Journal of Neuropsychiatry and Clinical Neurosciences, 1093-95.Google Scholar
  5. Cohen, S. A., & Underwood, M. T. (1994). The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry, 55440-444.Google Scholar
  6. Hammock, R. G., Schroeder, S. R., & Levine, W. R. (1995). Effects of clozapine on self-injurious behavior. Journal of Autism and Developmental Disorders, 25611-627.Google Scholar
  7. Kalachnik, J. (1988). Medication monitoring procedures: Thou shall, here's how. In K. D. Gradow & A. D. Poling (Eds.), Pharmacotherapy and mental retardation(pp. 231-268). Boston: Little, Brown.Google Scholar
  8. Kamal, M., & Kelly, M. (1999). The use of clozapine in an individual with moderate intellectual disability, aggressive behaviour and resistant psychosis. Irish Journal of Psychological Medicine, 1632-33.Google Scholar
  9. Meltzer, H. Y. (1994). An overview of the mechanism of action of clozapine. Journal of Clinical Psychiatry, 5547-52.Google Scholar
  10. Pary, R. J. (1994). Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders. Mental Retardation, 32323-327.Google Scholar
  11. Sajatovic, M., & Ramirez, L. (1995). Clozapine therapy in patients with neurological illness. International Journal of Psychiatry in Medicine, 25331-344.Google Scholar
  12. Sajatovic, M., Ramirez, L. F., Kenney, J. T., & Meltzer, H. Y. (1994). The use of clozapine in borderline-intellectual-functioning and mentally retarded and schizophrenic patients. Comprehensive Psychiatry, 3529-33.Google Scholar
  13. Schroeder, S. R., Hammock, R., Mulick, J. A., Rojahn, J., Walson, P., Fernald, W., Meinhold, P., and Sarphare, G. (1995). Clinical trials of D1and D2dopamine modulating drugs and selfinjury. Mental Retardation and Developmental Disabilities Research Reviews, 1120-129.Google Scholar
  14. Schroeder, S. R., Rojahn, J., & Reese, R. M. (1997). Reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. Journal of Autism and Developmental Disorders, 2789-102.Google Scholar
  15. Schroeder, S. R., Reese, R. M., Hellings, J., Loupe, P., & Tessel, R. E. (1999). The cause of self-injurious behavior and their clinical implicationsN. A. Wieseler & R. Hanson (Eds.), Challenging behavior of persons with mental health disorders and severe developmental disabilities(pp. 65-87). Washington, DC: AAMR Monograph Series.Google Scholar
  16. Sheiner, L. B., Beal, S. L., & Sambol, S. C. (1989). Study designs for dose-ranging. Clinical Pharmacology and Therapeutics, 4663-77.Google Scholar
  17. Sprague, R. L., Kalachnik, J. E., & White, D. M. (1985). Dyskinesia Identification System: Condensed User Scale (DISCUS). Champaign, IL: Institute for Child Behavior and Development.Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Ron Hammock
    • 1
  • William R. Levine
    • 2
  • Stephen R. Schroeder
    • 1
  1. 1.University of KansasLawrence
  2. 2.Creative Community Living, Inc.Winfield

Personalised recommendations